- Short name
- I-TRANSCEND
- Condition
- GPA, MPA
- Status
- Ongoing
- Study group
- Other studies
- Registry ID
- NCT07160608
- Links and documents
A phase 2 clinical trial assessing taperprumig, a novel targeted therapy, in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The study evaluates safety, efficacy, and its potential to reduce glucocorticoid exposure, with emphasis on remission rates and relapse prevention.